Literature DB >> 29651614

Antibiotics for recurrent acute pharyngo-tonsillitis: systematic review.

Holger Munck1, Anders W Jørgensen2, Tejs Ehlers Klug2.   

Abstract

The purpose was to determine the current evidence for preferable antibiotic treatment in three common clinical situations with insufficient consensus: Q1: Can antibiotic treatment prevent future attacks of acute pharyngo-tonsillitis (APT) in patients with recurrent APT (RAPT)? Q2: Which antibiotic regimen is preferable in the treatment of APT in patients with RAPT? Q3: Which antibiotic regimen is preferable in the treatment of relapsing APT? Five databases were searched systematically for randomized clinical trials on patients with RAPT with or without current APT or with relapse of APT. Of the unique publications, 643 were found. Five studies addressing Q1 (n = 3) and Q2 (n = 2) met the eligibility criteria. No studies reporting on Q3 were included. Q1: Two studies found that clindamycin and cefpodoxime, respectively, were effective in preventing future APT episodes and in eradicating group A streptococci from the tonsils of RAPT patients. One study found that long-term azithromycin had no effect on the number of APT episodes. Q2: Two studies reported superior clinical and microbiological effects of clindamycin and amoxicillin with clavulanate, respectively, compared to penicillin. The four studies showing superior effects of clindamycin and amoxicillin with clavulanate were assessed to have high risk of bias. Hence, the level of evidence was moderate. There is considerable evidence to suggest that clindamycin and amoxicillin with clavulanate are superior to penicillin with preferable effects on the microbiological flora and the number of future attacks of APT in patients with RAPT. Antibiotic treatment is an option in patients with RAPT, who has contraindications for tonsillectomy.

Entities:  

Keywords:  Amoxicillin with clavulanate; Antibiotics; Recurrent tonsillitis; Systematic review

Mesh:

Substances:

Year:  2018        PMID: 29651614     DOI: 10.1007/s10096-018-3245-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  44 in total

Review 1.  Reasons for failures in penicillin treatment of streptococcal tonsillitis and possible alternatives.

Authors:  S E Holm
Journal:  Pediatr Infect Dis J       Date:  1994-01       Impact factor: 2.129

2.  Bacterial invasion of the tonsillar tissues in acute pharyngotonsillitis and in the adenoid: a preliminary study.

Authors:  A Ebenfelt; C Lundberg
Journal:  Clin Otolaryngol Allied Sci       Date:  1994-08

3.  Clindamycin in recurrent group A streptococcal pharyngotonsillitis--an alternative to tonsillectomy?

Authors:  A Orrling; A Stjernquist-Desatnik; C Schalén
Journal:  Acta Otolaryngol       Date:  1997-07       Impact factor: 1.494

4.  Comparison of the microbiology of recurrent tonsillitis between children and adults.

Authors:  I Brook; P A Foote
Journal:  Laryngoscope       Date:  1986-12       Impact factor: 3.325

5.  Penetration of penicillin V to tonsillar surface fluid in healthy individuals and in patients with acute tonsillitis.

Authors:  A Stjernquist-Desatnik; P Samuelsson; M Walder
Journal:  J Laryngol Otol       Date:  1993-04       Impact factor: 1.469

Review 6.  Tonsillitis.

Authors:  Christos C Georgalas; Neil S Tolley; Professor Anthony Narula
Journal:  BMJ Clin Evid       Date:  2014-07-22

7.  Oral clindamycin 300 mg BID compared with oral amoxicillin/clavulanic acid 1 g BID in the outpatient treatment of acute recurrent pharyngotonsillitis caused by group a beta-hemolytic streptococci: an international, multicenter, randomized, investigator-blinded, prospective trial in patients between the ages of 12 and 60 years.

Authors:  Prasit Mahakit; José Gil Vicente; D Iqbal Butt; German Angeli; Sanjay Bansal; David Zambrano
Journal:  Clin Ther       Date:  2006-01       Impact factor: 3.393

8.  Fusobacterium necrophorum: most prevalent pathogen in peritonsillar abscess in Denmark.

Authors:  Tejs Ehlers Klug; Maria Rusan; Kurt Fuursted; Therese Ovesen
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

9.  In-vivo protection of group A beta-haemolytic streptococci from penicillin by beta-lactamase-producing Bacteroides species.

Authors:  I Brook; G Pazzaglia; J C Coolbaugh; R I Walker
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.